Proteasome inhibitors such as bortezomib have shown promise in ovarian cancer treatment but limitations like route of administration or severe side effects restrict their use. Targeting proteasomal ubiquitin receptor ADRM1, also known as RPN13, has emerged as an alternative strategy and some RPN13 inhibitors are in early development.